You are here: Home » PTI Stories » National » News
Business Standard

Glenmark Pharma to begin phase 2b clinical trial of atopic dermatitis drug

Press Trust of India  |  New Delhi 

Drug today announced initiation of phase 2b clinical trial of GBR 830, a novel for moderate-to-severe

"The trial's primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and pharmacodynamics," the company said in a BSE filing.

Trial enrollment is expected to begin in June 2018, it added.

said the results of the phase 2a trial completed last year demonstrated that GBR 830 was well-tolerated, and suggested signals of efficacy in the treatment of moderate-to-severe

Glenmark said in addition to moderate-to-severe atopic dermatitis, the company is also evaluating the potential for conducting studies with GBR 830 for the treatment of other

Preparations for a clinical trial assessing GBR 830 for the treatment of (SLE) are currently underway.

Shares of were trading 0.21 per cent higher at Rs 576 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 17 2018. 10:45 IST